Head-to-head · WeighScore
ElitePhysiqMD vs Trimi
By GLP-1 ScorecardUpdated
Score comparison
Trimi has the higher recorded score — 86.4/100 to 67.8/100.
Trimi grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Trimi combines compounded injections and care in monthly or prepaid plans; the annual discount is substantial, but prescription-issued refund limits deserve equal attention.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | ElitePhysiqMD | Trimi |
|---|---|---|
| WeighScore | 67.8/100 | 86.4/100 |
| Grade | C | B |
| Site position | #171 | #9 |
| Semaglutide | Selected quote required: 4-week 0.25 mg product option is $219; one-time $49 visit/$30 shipping or discounted refills plus $89/month membership. Activation timing needs confirmation. | $175/mo month-to-month · $99/mo only on a 12-month prepay ($1,188 in one charge) |
| Tirzepatide | Selected quote required: 4-week 2.5 mg option is $249; the $229 minimum is a 0.5 mg microdose. Membership and one-time fees are separate. | $235/mo month-to-month · $125/mo only on a 12-month prepay ($1,500 in one charge) |
| Coverage | Coverage not published | All 50 states |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Not confirmed |
Site position #171 · C
Strengths
- Publishes member and one-time purchase options; membership is separate from medication.
- Names a medical director and describes the prescribing clinician’s role.
- Explains 28-day and 84-day supply options, including quarterly billing for subscribed three-month packs.
- HSA/FSA eligible; accepts all 50 states with no insurance required
- Peptide therapy also available: NAD+, sermorelin, CJC-1295/ipamorelin, GHK-Cu, and glutathione
What to consider
- One-time orders add a $49 visit and $30 shipping; active membership advertises $0 visit/shipping with a separate $89 monthly fee.
- Lab upload and comparison are advertised; included bloodwork, testing charges and the selected monitoring plan were not established.
- Ongoing support is advertised; specific care access, response times and included nutrition services need confirmation.
- The $145 program headline does not settle the dose- and supply-specific product invoice or activation charge.
- Newer platform (founded late 2025); no Trustpilot rating or public patient reviews found
Site position #9 · B
Strengths
- Separate semaglutide and tirzepatide plans include prescribed medication and care
- Monthly, quarterly, six-month and annual charges published
- BelieveRx pharmacy and Arora Health care network publicly named; individual assignment and licenses still need confirmation
- Supplies and shipping included under the published offer
What to consider
- Compounded injections only; no current branded or oral route
- Monthly and quarterly plans renew automatically; six-month and annual continuation needs a new confirmed purchase
- Ordinary orders become nonrefundable once the prescription is issued, even before shipping
- A named pharmacy partner does not independently verify the pharmacy assigned to your order
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.